PREDICTION OF CLINICAL EFFICIENCY OF SIMVASTATIN TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS
https://doi.org/10.15789/1563-0625-2009-2-3-221-226
Abstract
Abstract. Treatment with statins results in reduction of disease activity in one-third of patients with rheumatoid arthritis (RA). The aim of this study was to assess some factors that may predict clinical response to simvastatin therapy before starting the treatment. We evaluated an association of treatment efficacy with baseline clinical and laboratory parameters including disease activity measures, cytokine profiles in sera and culture supernatants of peripheral blood mononuclear cells. Thirty-three patients with active RA were enrolled in the study. The patients were treated with simvastatin at 40 mg/day for three months. Eleven patients (33%) developed a moderate response according to EULAR criteria. It was shown that serum IL-10 concentrations was higher in responders, and positively correlated with clinical response to simvastatin. We carried out a receiver operating characteristic curve (ROC) analysis in order to assess the accuracy of serum IL-10 for the predicting of EULAR response development. The cut-off threshold corresponding to the highest sensitivity (89%) and specificity (62%) was a value of 6.5 pg/ml. In conclusion, the performance characteristics of serum IL-10 measurement proved to be good enough to predict EULAR response to simvastatin therapy in RA patients.
About the Authors
I. V. ShirinskyRussian Federation
V. S. Shirinsky
Russian Federation
References
1. Ширинский И.В., Желтова О.И., Соловьева Н.Ю., Ширинский В.С., Козлов В.А. Механизмы действия, эффективность и безопасность использования статинов при ревматоидном артрите // Российский иммунологический журнал. – 2008. – № 2-3. – С. 241.
2. Ширинский И.В., Желтова О.И., Соловьева Н.Ю., Ширинский В.С., Козлов В.А. Клиническая эффективность статинов при ревматоидном артрите – пилотное исследование // Медицинская иммунология. – 2007. – № 4-5. – С. 505 - 508.
3. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., Healey L.A., Kaplan S.R., Liang M.H., Luthra H.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis // Arthritis Rheum. – 1988. – Vol. 31. – P. 315-324.
4. Boyum A. Isolation of leucocytes from human blood. A two-phase system for removal of red cells with methylcellulose as erythrocyte-aggregating agent // Scand. J. Clin. Lab. Invest. Suppl. – 1968. – Vol. 97. – P. 9-29.
5. Cohen J. A power primer. // Psychol. Bull. – 1992. – Vol. 112. – P. 155-159.
6. Deyo R.A., Diehr P., Patrick D.L. Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation // Control. Clin. Trials. – 1991. – Vol. 12. – P. 142 - 158.
7. Fries J.F., Spitz P., Kraines R.G., Holman H.R. Measurement of patient outcome in arthritis // Arthritis Rheum. – 1980. – Vol. 23. – P. 137-145.
8. Greenwood J., Steinman L., Zamvil S.S. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation // Nat. Rev. Immunol. – 2006. – Vol. 6 – P. 358-370.
9. McCarey D.W., McInnes I.B., Madhok R., Hampson R., Scherbakov O., Ford I., Capell H.A., Sattar N. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebocontrolled trial // Lancet. – 2004. – Vol. 363. – P. 2015 - 2021.
10. Prevoo M.L., van ‘t Hof M.A., Kuper H.H., van Leeuwen M.A., van de Putte L.B., van Riel P.L. Modified disease activity scores that include twentyeightjoint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis // Arthritis Rheum. – 1995. – Vol. 38. – P. 44-48.
11. Seitz M., Zwicker M., Villiger P.M. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate // J. Rheumatol. – 2003. – Vol. 30. – P. 28-35.
12. Seitz M., Zwicker M., Wider B. Enhanced in vitro induced production of interleukin 10 by peripheral blood mononuclear cells in rheumatoid arthritis is associated with clinical response to methotrexate treatment // J. Rheumatol. – 2001. – Vol. 28. – P. 496-501.
13. Swets J.A. Measuring the accuracy of diagnostic systems // Science. – 1988. – Vol. 240. – P. 1285 - 1293.
14. van Gestel A.M., Prevoo M.L., van‘t Hof M.A., van Rijswijk M.H., van de Putte L.B., van Riel P.L. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization / International League Against Rheumatism Criteria // Arthritis Rheum. – 1996. – Vol. 39. – P. 34-40.
15. Yokota K., Miyazaki T., Hirano M., Akiyama Y., Mimura T. Simvastatin inhibits production of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor-alpha in fibroblastlike synoviocytes from patients with rheumatoid arthritis // J. Rheumatol. – 2006. – Vol. 33. – P. 463 - 471.
Review
For citations:
Shirinsky I.V., Shirinsky V.S. PREDICTION OF CLINICAL EFFICIENCY OF SIMVASTATIN TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS. Medical Immunology (Russia). 2009;11(2-3):221-226. (In Russ.) https://doi.org/10.15789/1563-0625-2009-2-3-221-226